Baudax bio Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

About Baudax bio Contact Number

Contact us to learn more about the company or our role in the acute care industry. Do not use this form to report adverse drug experiences. To report adverse drug experiences, please call (844) 303-5510

Contact US: https://www.baudaxbio.com/contact

Baudax

27 People Used

See More ››

Baudax Bio, Inc. (BXRX)

Baudax Bio Announces Special Meeting of Shareholders to Vote on Proposed Increase in Number of Authorized Shares of Common Stock View Press Release Jun 10, 2021 • 7:00 AM EDT

View Contact ››

Therapeutics

53 People Used

See More ››

Baudax Bio

Therapeutics. Headquarters Regions Greater Philadelphia Area, Great Lakes, Northeastern US. Founded Date Jan 1, 2015. Operating Status Active. Stock Symbol NASDAQ:BXRX. Company Type For Profit. Contact Email [email protected]baudaxbio.com. Phone Number 484-395-2440.

View Contact ››

Baudax

35 People Used

See More ››

About :: Baudax Bio, Inc. (BXRX)

Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for patients in acute care settings. We are committed to bringing clinically meaningful therapeutic options to patients, health care providers, and payers, such as ANJESO® (meloxicam) injection, which was approved by the U.S. Food and Drug Administration (FDA) in February 2020.

View Contact ››

Formulary

38 People Used

See More ››

Careers :: Baudax Bio, Inc. (BXRX)

The ACS will be the primary point of contact for Baudax Bio with key hospital influencers and decision makers across key functional areas including but not limited to surgeons, anesthesiologists, pharmacists and formulary committee members. Acute Care Specialist – Denver, CO: Apply Now

View Contact ››

Baudax

65 People Used

See More ››

Press Releases :: Baudax Bio, Inc. (BXRX)

Baudax Bio Announces Special Meeting of Shareholders to Vote on Proposed Increase in Number of Authorized Shares of Common Stock Jun 18, 2021 4:05pm EDT Baudax Bio to Participate in the JMP Securities Life Sciences Conference

View Contact ››

Information

64 People Used

See More ››

Baudax Bio, Inc.

Baudax Bio, Inc. – Certain information in this document has been excluded pursuant to Regulation S-K, item 601(b)(10) Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. CREDIT AGREEMENT dated as of May This Credit Agreement dated as of May 29, 2020 (as amended, restated, supplemented or otherwise modified from time

View Contact ››

Business

53 People Used

See More ››

Baudax Bio, Inc. (BXRX) Company Profile & Facts

See the company profile for Baudax Bio, Inc. (BXRX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their

View Contact ››

Baudax

51 People Used

See More ››

Baudax Bio LinkedIn

Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for patients in acute care settings. Baudax Bio

View Contact ››

Baudax

170 People Used

See More ››

Baudax Bio Announces the Cancellation of Adjourned Portion

Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings. The launch of Baudax Bio’s first commercial product ANJESO® began

View Contact ››

CONTACT

82 People Used

See More ››

Baudax Bio Announces $17.6 Million Offering Priced At the

CONTACT: Investor Relations Contact: Argot Partners Sam Martin / Claudia Styslinger (212) 600-1902 baudaxbio@argotpartners.com Baudax Bio, Inc. Ryan D. Lake (484) 395-2436 [email protected]baudaxbio.com

View Contact ››

Baudax

87 People Used

See More ››

Baudax Bio Announces Special Meeting of Shareholders to

Shareholders needing assistance voting or have questions may contact the Company’s proxy solicitation firm, Okapi Partners, at [email protected] or (855) 208-8902. About Baudax Bio. Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings.

View Contact ››

Baudax

81 People Used

See More ››

Baudax Bio Announces $11.9 Million Registered Direct Offering

The warrants have an exercise price of $0.90 per share, will become exercisable upon the later of (i) the six-month anniversary of the closing date of the offering, and (ii) the date of approval by the Baudax Bio shareholders of an increase in the number of Baudax Bio’s authorized shares of common stock, and will expire on December 1, 2026.

View Contact ››

Please leave your comments here:

Popular Brands

Bpost
Bce
Bvb
Brf